On May 27, 2022 NEX-I reported the company has established 20 types of mouse models for refractory factors, and developed ‘NX-101,’ a candidate for an immunotherapy agent targeting solid tumors (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=18&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643435]). "We plan to complete non-clinical trials within next year and enter phase 1 clinical trials in the fourth quarter of next year."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NEX-I was founded in April last year by CEO Kyung-Wan Yoon, who served as Chief Scientific Officer (CSO) and Vice President at Genome & Company. Currently, about 15 people are working at Nexi, including Chief Operating Officer (COO) Vice President Son Jin-beop, and Chief Technology Officer (CTO) Professor Kim Tae-woo of Korea University, who are former DM Bio employees, and plans to add about 10 more people this year.

NexI was selected for the TIPS and Korea New Drug Development Foundation (KDDF) ​​project last year, and attracted 4 billion won in pre-Series A. In particular, we will cooperate in the mid- to long-term with Daewoong Pharmaceutical, which participated as a strategic investor in Pre Series A, to develop pipelines such as non-small cell lung cancer (NSCLC) antibody candidate ‘NXI-101’ and metastatic melanoma antibody candidate ‘NXI-201’. We plan to continue research and development.